1 / 33

Stem Cell Therapeutics Corp.

Stem Cell Therapeutics Corp. SCTPF – OTCQX SSS – TSXV. A clinical-stage public company developing therapies targeting cancer stem cells. Q3, 2013. DISCLAIMER.

cece
Download Presentation

Stem Cell Therapeutics Corp.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Stem Cell Therapeutics Corp. SCTPF – OTCQX SSS – TSXV A clinical-stage public company developing therapies targeting cancer stem cells Q3, 2013

  2. DISCLAIMER This presentation may contain forward-looking statements, which reflect SCT's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, SCT's ability to obtain financing to advance the products in its development portfolio; changing market conditions; the successful and timely completion of pre-clinical and clinical studies; the establishment of corporate alliances; the impact of competitive products and pricing; new product development risks; uncertainties related to the regulatory approval process or the ability to obtain drug product in sufficient quantity or at standards acceptable to health regulatory authorities to complete clinical trials or to meet commercial demand; and other risks detailed from time to time in SCT's ongoing quarterly and annual reporting. Except as required by applicable securities laws, SCT undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

  3. Corporate Overview • Strong scientific foundation • Focused on oncology and cancer stem cells: • Merged with Trillium Therapeutics, a private biopharmaceutical company with strong focus on immunotherapy & cancer stem cells • Acquired worldwide rights to a clinical-stage repurposed cancer stem cell program • Company has an extensive academic and clinical network in Toronto, a centre at the forefront of stem cell research • SCT is uniquely positioned to be the preferred receptor company for emerging cancer stem cell technologies • Experienced corporate leadership with demonstrated resilience and success

  4. Merger with Trillium – Creating a More Complete Oncology Company Trillium Therapeutics SIRPaFc & CD200 mAb Assets Tigecycline Asset Management Stem Cell Therapeutics Access to Capital R&D Infrastructure Public Listing The new SCT has an exciting portfolio of oncology assets, an experienced management team and R&D capabilities

  5. Dr. John Dick PhD, FRSC: Credited with the first identification of leukemic stem cells Canada Research Chair in Stem Cell Biology, U of Toronto Director, Program in Cancer Stem Cells, Ontario Institute for Cancer Research Dr. Aaron Schimmer MD, FRCPC, PhD: Clinician-Scientist, Ontario Cancer Institute, University Health Network; U of T 2012 recipient of Till & McCulloch Award for exceptional stem cell research Principal Investigator on nine clinical trials in leukemia; >100 publications Solid Scientific Foundation

  6. Pipeline Research Preclinical Phase I Phase II Phase III Cancer SIRPaFc Cancer CD200 mAb Acute Myeloid Leukemia (AML) Tigecycline Interstitial Cystitis/Bladder Pain Syndrome TTI-1612* *Non-core Trillium legacy program (to be outlicensed)

  7. Recent News FOR IMMEDIATE RELEASE TSX-V: SSS OTCQX: SCTPF STEM CELL THERAPEUTICS ACQUIRES AN EXCLUSIVE OPTION TO LICENSE PROSTATE CANCER STEM CELL ASSETS Collaboration with Internationally Renowned Prostate Cancer Research Group Toronto, Canada – August 9, 2013 – Stem Cell Therapeutics Corp. (TSX-V: SSS; OTCQX: SCTPF), a biopharmaceutical company developing cancer stem cell-related therapeutics, today announced that it has entered into an option agreement to exclusively license worldwide rights to a series of prostate cancer stem cell assets from the University of York, United Kingdom. The assets originate from research funded by Yorkshire Cancer Research (YCR) and conducted in the YCR Cancer Research Unit, University of York, under the direction of Professor Norman Maitland. Stem Cell Therapeutics (SCT) intends to work closely with the Maitland group, leveraging its internal scientific strengths and its existing global network of collaborators.

  8. Capitalization • Common shares outstanding 42.5 M • Fully diluted (avg. conversion $0.45) 65.2 M • Market capitalization (recent) $20 M • 52 week range $0.14 to $0.60 • Price last raise (March 2013) $0.25 • Avg. daily volume (12 months) 121,000 • Holders: • Institutions ~ 28% • Insiders ~ 8%

  9. Valuation Targets • Verastem (VSTM): Market cap ~$320M • Stemline (STML): Market cap ~$390M • Oncomed (OMED):Market Cap ~$540M • Immunocellular Therapeutics (IMUC): Market cap ~$175M • Boston Biomedical: Acquired for $200M up-front & $540M earn-out • Arius Research: Acquired for $191M

  10. Investment Attributes Strong scientific foundations – competitive with peer group Sound immunotherapy/cancer stem cell programs CD47; an immunotherapy target of high industry interest Novel mechanisms of action Multiple cancers beyond AML De-risked model – tigecycline – repurposed, FDA-approved, marketed drug Experienced corporate leadership with demonstrated resilience and success

  11. Near Term Milestones Targeted TTI-1612 Program Tigecycline Program SIRPaFc Program Corporate 1612 study complete Complete tigecycline re-formulation Tigecycline dosing complete SIRPaFc program partner discussions Additional tigecycline cohorts added if no MTD ASH abstract Publish 1612 study results NHP study complete SIRPaFc IND-enabling initiation Initiate NCE program Tigecycline OD designation Aug-13 Jan-14 May-13 Jun-13 Jul-13 Sep-13 Oct-13 Nov-13 Dec-13 Feb-14 Mar-14 Apr-14 OTCQX listing Amplify Clinical Advisory Board New board member added License new preclinical asset 11

  12. Why Cancer Stem Cells (CSCs)? CSCs are rare cells found within tumors that have stem cell-like properties They are resistant to conventional chemotherapy and radiation treatment Responsible for tumor relapse and death First isolated in acute myeloid leukemia (AML), but also present in numerous other cancers (breast, colon, etc.) Eliminating CSCs is the critical missing element in cancer therapy Tumor containing rare CSCs CSCs survive chemotherapy and radiation Tumor re-grows from CSCs

  13. Two Unique Approaches toTargeting CSCs SIRPaFc Tigecycline A novel biologic that activates the immune system to kill CSCs A re-purposed small molecule targeting the CSC energy supply Tumor bulk AND CSCs destroyed

  14. Initial Focus:Acute Myeloid Leukemia (AML) • Strong evidence that AML is sustained by CSCs • Most common adult leukemia (~13,000 cases/yr in US) • Treatment and outcomes largely unchanged over the last 20 years • Patients older than age 60 have very poor prognosis: <20% survival at 2-years • Demographics driving dramatic growth in incidence SEER Cancer Statistics Review 1975-2008, NCI 2011

  15. SIRPaFc A pre-IND immunotherapy program Macrophage phagocytosis of a cancer cell – SIRPaFc activates macrophages to kill tumors

  16. CSCs Escape Macrophage Killing Using CD47, a “Do Not Eat” Signal • Macrophages can phagocytose (“eat”) tumor cells • Tumor cells, especially CSCs, escape destruction by over-expressing CD47, a molecular “do not eat” signal that binds SIRPa receptor on macrophages • Elevated CD47 expression is associated with poor survival in cancer patients Tumor cells protected from macrophages by CD47 When CD47 is blocked, tumor cells are engulfed AML tumor cells in green Human macrophages in red

  17. SIRPaFc: A Novel Biologic thatBlocks the CD47 “Do Not Eat” Signal SIRPaFc is an antibody-like recombinant fusion protein It binds to CD47 with high affinity and acts as a decoy, blocking the delivery of the “do not eat” signal to macrophages Proprietary design based on detailed optimization studies Promotes macrophage-mediated destruction of tumor cells and has an excellent safety profile CSC CSC CD47 SIRPa M M Phagocytosis Blocked Phagocytosis Enabled CSCs Survive CSCs Destroyed

  18. SIRPaFc Enables Human Macrophages to Kill AML Cells No Treatment Control Fc (10 mM) SIRPaFc (10 mM) • Human AML cells labeled green (CSFE dye) • Human macrophages labeled red (Alexa Fluor-555 dye) • Phagocytosis assessed by confocal microscopy after 2 hr co-culture

  19. SIRPaFc Has Potent Anti-leukemic Activity In Vivo • Human AML cells injected intrafemorally into irradiated NOD.SCID mice • Mice treated with SIRPaFc or control IgG Fc protein (8 mg/kg IP 3x/wk for 4 wks) starting on day 10 • Leukemia in the injected right femur (RF), non-injected bone marrow (BM) and spleen (SP) assessed after 4 wks of treatment Theocharides et al. 2012 J. Exp. Med. 209:1883

  20. SIRPaFc tolerability in vivo Human SIRPaFc proteins do not cross-react with mouse CD47; mouse surrogate fusions have been generated to evaluate tolerability in vivo Mouse surrogates are extremely well tolerated, even at doses 10x higher than the efficacious dose Excellent tolerability profile consistent with published reports using anti-CD47 mAb with similar affinity for target Absence of necessary pro-phagocytic signals (e.g., calreticulin) on normal cells may limit non-specific macrophage killing

  21. Tigecycline A clinical stage drug program targeting the tumor energy supply Mitochondria inside a cell – Mitochondria in AML CSCs are particularly sensitive to inhibition by tigecycline

  22. Tigecycline: Re-purposing an Approved Antibiotic for Cancer • Dr. Aaron Schimmer demonstrated that tigecycline has potent activity against leukemia cells and leukemic stem cells* • This discovery was awarded the 2012 Till & McCulloch Award • Discovery protected by several layers of patent filings • Clinical trial in AML patients ongoing Tigecycline (TygacilTM) is a tetracycline-class, intravenous antibiotic approved to treat serious infections *Skrtic et al. 2011 Cancer Cell 20:674

  23. Tigecycline Kills CSCs Drug library screen using two leukemia cell lines with CSC-like properties Viability of CSCs (CD34+CD38-) after treatment of primary AML cells with tigecycline Skrtic et al. 2011 Cancer Cell 20:674

  24. Tigecycline for the Treatment of AML Tigecycline reduces leukemia in xenograft studies but does not affect normal hematopoietic stem cells Synergizes with daunorubicin, a standard chemotherapy used in AML patients Unique mechanism of action – targets the CSC energy supply by suppressing mitochondrial protein synthesis Drug preferentially accumulates in the bone marrow, the CSC niche A multi-center, phase I study in AML patients currently underway; expected completion in mid 2013

  25. Current Clinical Status Tigecycline (Tygacil®) is being evaluated patients with treatment-refractory AML or patients without prior treatment that are not eligible for induction therapy Primary objective is to establish maximum tolerated dose and recommended phase II dose 7 dose cohorts (50 – 350 mg/day) administered IV daily x 10 doses Most doses exceed anti-infective doses (100 mg/day) 4 sites: Princess Margaret Hospital (Toronto), UCLA Medical Center, University of Kansas Medical Center & Memorial Sloan-Kettering (New York)

  26. Tigecycline: Re-purposing aNew Formulation Re-purposing approved drugs reduces development risk and cost, by leveraging the compound’s existing safety profile Current marketed product (Tygacil®) is ill-suited for oncology use due to poor liquid stability and emerging generic competition SCT is evaluating three paths forward: Re-formulate using common excipients already in use for IV products (simple regulatory path) Develop a novel formulation through an expanded research program (will require some additional safety studies) Develop an analogue (NCE) through accessing medchem (will require completely new drug development program)

  27. Current IP position SIRPaFc: Broad claims to blockade of the CD47/SIRPa interaction for the treatment of CD47+ cancers (WO2010/130053) SIRPaFc compositions (US provisional) Tigecycline: Use of Tigecycline to treat cancer (WO2011/109899) Combination with standard chemo (PCT/CA2012/000675) Reformulated compositions (PCT/CA2012/001114) Combination with class of targeted agents (US provisional) Orphan Drug filing in AML (US/EU)

  28. SCT Pipeline Expansion Both SIRPaFc and Tigecycline programs have strong potential beyond AML: Growing list of cancers that exploit the CD47 pathway SIRPaFc has been shown to have activity in an another leukemia indication and potential for use in solid tumors is high Emerging data on synergy between Tigecycline and approved class of signalling inhibitors; possibility to expand into other leukemias and solid tumors Access to additional CSC assets from UHN As a preferred receptor company for academic cancer stem cell discoveries, CSC technologies are under continuous evaluation

  29. CD200 mAb to Augment Anti-tumor Immunity • CD200 is an immunosuppressive molecule expressed by many hematological and solid tumors • CD200 expression allows tumors to escape immune attack • Disruption of the CD200-CD200R pathway leads to enhanced immune activity in animal models of cancer and autoimmunity • A fully human CD200 blocking mAb is being developed to alleviate CD200-mediated immune suppression and promote anti-tumor responses • Program is ready for IND-enabling studies

  30. TTI-1612 for the Treatment of IC • IC is a chronic, debilitating and poorly treated bladder condition that affects millions of people in the US (90% women) • Defective (“leaky”) bladder epithelium plays a major role in disease development • TTI-1612 (recombinant HB-EGF) stimulates the proliferation and reduces the permeability of IC bladder epithelial cells • IC patients have reduced urinary levels of HB-EGF, which may contribute to epithelial dysfunction • TTI-1612 is being developed as a local (intravesical) therapy to correct the epithelial dysfunction in IC patients • Phase I trial completed in IC patients; seeking partner for Phase II

  31. Strong Leadership Dr. Niclas Stiernholm – President & CEO 15+ years pharma/biotech experience Founding CEO Trillium Therapeutics; Executive Vice-President & CSO, YM BioSciences; Allelix Biopharmaceuticals Dr. Robert Uger – CSO 10+ years pharma/biotech experience Vice President, Research & Development at Trillium Therapeutics; Aventis Pasteur Dr. Penka Petrova – Vice President, Drug Development 10+ years biotech experience Director of Drug Development at Trillium Therapeutics; Prescient Neuropharma Mr. James Parsons – CFO 20+ years of financial management experience VP Finance/CFO DiaMedica; Amorfix; Lorus Therapeutics

  32. Experienced Board of Directors Mr. David Allan (Chairman) Founding Chairman and CEO of YM BioSciences Inc Dr. James DeMesa Senior pharma/biotech executive (Migenix, GenSci Rengeneration Sciences, Biodynamics) Dr. Henry Friesen Former President of Canadian Medical Research Council and National Cancer Institute Dr. Michael Moore Former CEO and Director of PIramed Ltd, CSO Xenova Mr. Dean Peterson Calgary-based entrepreneur Dr. Niclas Stiernholm President & CEO Dr. Calvin Stiller Co-Founder, Cancer Stem Cell Initiative and Chair, Ontario Institute for Cancer Research

  33. Summary SCT is focused in the oncology and cancer stem cell space Through recent transactions, SCT has built an exciting pipeline of oncology assets and acquired strong management & infrastructure Marked presence in the cancer stem cell arena with two highly competitive programs Novel mechanisms of action Innovative and proprietary Potential for broad application across multiple types of cancer De-risked and focused business model Steady flow of near-term clinical and non-clinical value inflection points

More Related